• Latest
  • Trending
Summit Therapeutics (SMMT) Stock Drops After FDA Rejects Lung Cancer Drug Application

Summit Therapeutics (SMMT) Stock Drops After FDA Rejects Lung Cancer Drug Application

November 17, 2026
CFTC Makes Historic Move With Blockchain Derivatives Approval

CFTC Makes Historic Move With Blockchain Derivatives Approval

November 17, 2026
Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

November 17, 2026
Figment to Support Staking on BNY’s Custody Platform

Figment to Support Staking on BNY’s Custody Platform

November 17, 2026
AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

November 16, 2026
Trezor Customer Data Exposed in Third Partner Breach

Trezor Customer Data Exposed in Third Partner Breach

November 16, 2026
Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

November 16, 2026
TSMC (TSM) Stock Drops 6% as Nvidia CEO Exit Rattles Asian Chip Names

TSMC (TSM) Stock Drops 6% as Nvidia CEO Exit Rattles Asian Chip Names

November 16, 2026
7 Major Banks Reveal XRP ETF Holdings in Latest SEC Filings

7 Major Banks Reveal XRP ETF Holdings in Latest SEC Filings

November 16, 2026
Hong Kong Reaffirms Year-End Crypto Licensing Bill

Hong Kong Reaffirms Year-End Crypto Licensing Bill

November 16, 2026
  • Privacy Policy
Tuesday, November 17, 2026
MtRushmoreCrypto - Where Crypto Rocks
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us
No Result
View All Result
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us
No Result
View All Result
Logo
No Result
View All Result
Home Crypto Technical Analysis

Summit Therapeutics (SMMT) Stock Drops After FDA Rejects Lung Cancer Drug Application

J_News by J_News
November 17, 2026
in Crypto Technical Analysis, Top News
0
Summit Therapeutics (SMMT) Stock Drops After FDA Rejects Lung Cancer Drug Application
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter


Follow on Google News

TLDR

  • The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer.
  • SMMT fell about 17% in premarket trading to near $11.70.
  • The agency wants a statistically significant overall survival gain.
  • Jefferies sees limited downside, while Barclays cut its target to $18.
  • Summit says its commitment to ivonescimab is unchanged.

Summit Therapeutics (SMMT) stock dropped about 17% in premarket trading on Monday, landing near $11.70. That puts it at a new 52-week low.


SMMT Stock Card
Summit Therapeutics Inc., SMMT

The trigger came on Sunday, when the FDA sent a Complete Response Letter on the company’s drug application. The letter says ivonescimab cannot be approved in its current form.

The application covered ivonescimab paired with platinum-containing chemotherapy. It targets locally advanced or metastatic non-small cell lung cancer in patients who already tried an EGFR tyrosine kinase inhibitor.

The stock had climbed as high as $29.23 over the past year. It now sits close to the bottom of that range, around $12.07.

What the FDA Said

The agency ruled that Summit did not show substantial evidence of effectiveness. The missing piece was a statistically significant improvement in overall survival.

Progression-free survival gains alone were not enough, the FDA said. It wants the survival data to back up the benefit-risk case.


Betpanda


The Phase 3 HARMONi trial did hit its progression-free survival goal. The overall survival result, however, fell short of statistical significance.

Related articles

CFTC Makes Historic Move With Blockchain Derivatives Approval

CFTC Makes Historic Move With Blockchain Derivatives Approval

November 17, 2026
Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

November 17, 2026

Summit pointed out that the combination still showed a positive overall survival trend. It also noted that no approved regimen in this setting has shown a statistically significant survival benefit.

A later analysis with longer follow-up of Western patients gave a hazard ratio of 0.76. That figure held across the full group, Asian patients and Western patients.

The safety profile was described as manageable. There were no new safety signals, and discontinuation and death rates were similar across both trial arms.

Analysts and Partners React

Jefferies called the rejection the base case for investors. The firm sees limited downside because second-line EGFR was never central to the investment story.

Jefferies also said Summit had earlier shared that it was not aligned with the FDA on this filing. Its eyes are now on HARMONi-3 squamous progression-free survival data, expected around the end of 2026.

Barclays kept its Equalweight rating on the stock. It trimmed its price target to $18 from $20.

Akeso, Summit’s partner, issued a notice on Monday about abnormal stock price swings. That came after Summit’s press release on Sunday.

The wider market offered no cushion. The Nasdaq closed down 0.91% on Friday, and tech weakness carried into the new week.

No regulator in Summit’s license territories, including the U.S. and Europe, has approved ivonescimab. China approved the drug in May 2024.

Summit says its plans are unchanged. It cited five positive Phase III studies across Summit and Akeso.



Source link

ShareTweetShareShare

Related Posts

CFTC Makes Historic Move With Blockchain Derivatives Approval

CFTC Makes Historic Move With Blockchain Derivatives Approval

by J_News
November 17, 2026
0

The U.S. Commodity Futures Trading Commission (CFTC) has opened historic doors for blockchain technology adoption in traditional financial markets as it...

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

by J_News
November 17, 2026
0

Key TakeawaysMeta staff are testing Takes, a prediction app that uses points called “cred” instead of money, WSJ reported.Meta declined...

Figment to Support Staking on BNY’s Custody Platform

Figment to Support Staking on BNY’s Custody Platform

by J_News
November 17, 2026
0

TL;DR Figment will provide validator infrastructure for BNY's institutional staking offering. Eligible clients would access staking within the bank's digital...

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

by J_News
November 16, 2026
0

TLDR AMD stock fell about 5% to $508.16 in Monday premarket trading after a 9% drop on Friday. The stock...

Trezor Customer Data Exposed in Third Partner Breach

Trezor Customer Data Exposed in Third Partner Breach

by J_News
November 16, 2026
0

Hardware wallet maker Trezor has disclosed its third partner data breach this year, warning that an attacker accessed personal information...

Load More

Enter your email address:

Delivered by FeedBurner

Quick Navigate

  • Home
  • Crypto
  • Crypto Technical Analysis
  • Top News
  • Thank You
  • Store
  • About Us

Top News

Gram Price: Jumps 9% as Telegram Opens Money Wallet to More Users

Best Perp DEXes in 2026: Hyperliquid, Aster, Lighter, edgeX, and ApeX Omni Compared

Why Does Ethereum Gas Estimation Fail?

© 2021 mtrushmorecrypto - Crypto Related News Blog

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
No Result
View All Result
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us

© 2021 mtrushmorecrypto - Crypto Related News Blog